Carthera announces positive outcome of End-of-Phase 2 meeting with FDA for SonoCloud-9 system for treatment of recurrent glioblastoma

Carthera and FDA aligned on key aspects of proposed pivotal trial design

Paris, France, March 13, 2023 – Carthera, a French company that designs and develops the SonoCloud®, an innovative ultrasound-based medical device to treat a wide range of brain diseases, announces today the completion of its End-of-Phase 2 meeting with the US Food & Drug Administration (FDA).

Read the press release